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Abstract—Identification of intracellular pathways that play key roles in
cancer progression and drug resistance is a prerequisite for developing
targeted cancer treatments. The era of personalized medicine calls for
computational methods that are able to function with one sample or very
small set of samples. Developing such methods is challenging because
standard statistical approaches pose several limiting assumptions, such
as number of samples, that prevent their application when n approaches
to one. We have developed a novel pathway analysis method called
PerPAS to estimate activity of pathways at a single sample level by
integrating pathway topology information and transcriptomics data. In
addition, PerPAS is able to identify altered pathways between cancer
and control samples as well as to identify key nodes that contribute to
the pathway activity. In our case study using breast cancer data, we
show that PerPAS is able to identify highly altered pathways that are
associated with patient survival. PerPAS identified four pathways that
were associated with patient survival and were successfully validated in
at least three independent breast cancer cohorts. In comparison to two
other pathway analysis methods that function at a single sample level,
PerPAS had superior performance in both synthetic and breast cancer
expression datasets. PerPAS is freely available as an R package with
full documentation at http://csbi.ltdk.helsinki.fi/pub/czliu/perpas/.
Index Terms—Computational biology, bioinformatics, pathway analysis,
integration, gene expression.
1 INTRODUCTION
Akey finding from large-scale cancer sequencing ef-forts is that histologically similar cancers may have
very different genomic landscapes and treatment responses.
Accordingly, cancer genomics data have been increasingly
used to identify cancer subtypes and to suggest targeted
therapies [1]. For example, in breast cancer, five subtypes
have been suggested based on transcriptomics profiling [2]:
luminal A, luminal B, HER2-enriched, basal-like and normal
breast-like. While these efforts have improved the use of
the right treatment for the right patient, samples belonging
to these subtypes still have significant heterogeneity at the
molecular level. Triple-negative breast cancers, which are
the major constituent of the basal-like subtype, have been
recently classified into six subtypes with different survival
time [3], [4]; luminal A subtype has been categorized into
four subtypes [5] and two subtypes have been identified
for breast cancer patients with the luminal B signature [6],
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[7]. Identification of smaller and clinically relevant subtypes
calls for computational methods that enable analysis of data
from a single or few samples.
Alterations in intracellular pathways can have a drastic
effect to efficacy of a therapeutic intervention, in particular,
targeted therapies. Thus, a number of pathway analysis
methods, such as SPIA [8], DEAP [9], DERA [10] and
PATHOME [11], have been developed to pinpoint altered
pathways. However, the majority of the existing methods
are based on comparison of groups of samples, and their
use is limited to settings where the number of samples
is sufficiently large to allow statistical inference. Recently,
some pathway analysis methods for small sample size have
been suggested. PARADIGM uses multi-level data from
single or few samples to infer activity of pathways [12]; iPAS
quantifies pathway aberration at a single sample level by
calculating average distance of a cancer sample from control
samples [13]; and Pathifier assigns pathway specific scores
that represent deviation from control samples [14]. The main
issues with these methods are that they require multi-level
data or they consider a pathway as a list of genes and do
not take pathway topology into consideration [8], [15], [16].
We have developed a novel computational method
called PerPAS (Personalized Pathway Alteration analysiS)
for the identification of altered pathways for a single sample
based on transcriptomics data. PerPAS uses pathway topol-
ogy information to quantify contribution of an aberrantly
expressed gene to pathways and further to characterize
pathway activity. Here, we use both breast cancer and
synthetic expression data to demonstrate the performance of
PerPAS and to compare it to single-sample based pathway
analysis methods iPAS and Pathifier.
2 RESULTS
2.1 Overview of PerPAS
PerPAS is designed to quantify pathway activity at a single
sample level. The major steps in the PerPAS approach are:
preprocessing transcriptomics and pathway data, quantify-
ing gene contribution to a pathway, and calculating per-
sonalized pathway activity scores (Fig. 1). Briefly, PerPAS
uses control samples to standardize gene expression profiles
and extracts pathways from databases (Fig. 1a). PerPAS
quantifies contribution of a gene to a pathway by taking
pathway topology, such as bottlenecks, which are defined as
nodes with high betweenness centrality [17], and hubs [15],
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Fig. 1. Schematic overview of personalized pathway alteration analy-
sis. Main steps: a) Gene expression data are transformed into standard-
ized matrix. From pathway databases, gene regulatory pathways are
retrieved. b) Gene contribution to a pathway is quantified by taking path-
way topology into account. Both topological bottleneck and hub roles
are considered. Bottleneck role is quantified by calculating how much
signaling the gene mediates while the hub role is modeled by how many
downstream genes it directly regulates and how much downstream
expression change it induces. c) Pathway activity score at an individual
sample level is calculated by summing all the gene contribution to the
pathway. d) Pathway activity score matrix for individual samples is used
to identify altered pathways deviated from baseline activity. Pk denotes
for a pathway.
[16], into account (Fig. 1b). Bottlenecks measure essentiality
of genes in mediating signaling whereas a hub is a highly
connected node in a pathway. Quantified gene contribution
to a pathway is further summarized to estimate the per-
sonalized pathway activity scores (Fig. 1c). The output of
PerPAS is a list of pathway activity scores for each sample
(Fig. 1d).
2.2 Utility of topology information in pathway analysis
Not all proteins in a pathway are equally important but
some, such as bottlenecks [17] and hubs [15], [16], have
bigger impact to the pathway activity and outcome than
proteins located more peripherally. Accordingly, a central
design principle behind PerPAS is to use topological in-
formation in the pathway analysis. To demonstrate the
importance of topological information and PerPAS, we gen-
erated three pathways with varying topology (Fig. 2a) and
used PerPAS to indicate the most influential nodes in these
pathways.
In the pathway with strong connection (Pc), Node 2 is a
bottleneck (Fig. 2a) and therefore its role in the pathway
is stronger than most of the other genes, such as Node
4. Obviously, the higher importance of Node 2 over Node
4 should be reflected in the results of pathway analysis.
PerPAS results indicate that the contribution of Node 2 in
the bottleneck role to the pathway Pc is 8.7 times higher
than that of Node 4 (Fig. 2b). In our study, the contribution
of the bottleneck role is represented as a fraction of signaling
flows that go through a particular node over all the signaling
flows in the pathway. The value ranges from 0 to 1 (See more
details in Methods).
Node 3 is another important node since it is a hub and
it regulates four downstream genes out of ten genes in
the pathway Pc (Fig. 2a). Although Node 3 itself is not
differentially expressed, its downstream genes are (Fig. 2a).
Hence, it is valuable to take hub roles into account when
performing pathway analysis. PerPAS results indicate the
hub role of Node 3 is not concealed by the fact of its un-
changed expression in the pathway Pc (Fig. 2c). In our breast
cancer study, the contribution of a hub role is modeled
as mean of gene expression of all its direct downstream
genes. This allows for identification of nodes with subtle
expression changes that do not pass statistical testing but
are clearly of biological interest.
By combining the bottleneck and hub roles of genes, Per-
PAS quantifies the contribution of each gene to the pathway
and ranks genes (Fig. 2d). PerPAS results show that Node 2
and Node 3 are the most important genes in the pathway Pc,
which is consistent with the fact that Node 2 and Node 3 are
a hub and a bottleneck, respectively.
In addition to ranking nodes in a pathway based on their
influence, PerPAS is also able to compare their contribution
to different pathways. For instance, in Pb Node 3 is a hub
and activates Node 8, whereas in Pc Node 3 is not only a hub
but also a bottleneck. It is the only bridge from Node 1, 5 and
7 to Node 4, 6, 8, 9 and 10 (Fig. 2a). The increased importance
of Node 3 to the pathway in Pc is quantified by PerPAS that
estimates the contribution of Node 3 as 0.08 in Pb and 0.20 in
Pc (Fig. 2d).
Pathway analysis methods that do not take topology
information into account, such as iPAS and Pathifier, will
produce identical results for the cases Pa, Pb and Pc. Thus,
they are not able to rank Node 3 higher and thus may fail to
identify biologically important nodes.
2.3 Identification of pathways and nexus genes in
breast cancer
In order to demonstrate that PerPAS is able to produce
robust and potentially important results, we have applied
PerPAS to a large breast cancer cohort from The Cancer
Genome Atlas (TCGA) (n = 984). The most interesting
findings were validated in four other breast cancer cohorts
GSE1456 (n = 159), GSE3494 (n = 236), GSE4922 (n = 249)
and GSE7390 (n = 198).
PerPAS identified 40 pathways that were significantly al-
tered in the breast cancer samples compared to the controls
in the TCGA cohort (t-test q < 10−60). Out of 40 altered
pathways, seven were significantly associated with breast


































































































































































































Fig. 2. Utility of PerPAS on synthetic data. a) Three synthetic pathways are manually created. Expression values of each gene in three pathways
are identical. However, these pathways have different topology, no connection (Pa), weak (Pb) and strong connection (Pc). Node sizes associate
with their topological hub role to the pathway. Red, green and gray colored nodes represent over, under and unchanged expression, respectively,
compared to control samples. Their corresponding gene expression values are 1, -1, and 0. b) Gene contribution to the pathways in bottleneck
role. Y axis indicates the percentage of signaling flows going through a particular gene given all signaling flows in the pathway. Contribution of
bottleneck role scales from 0 to 1. Zero indicates none of signaling goes through the gene while 1 indicates all the signaling flows go through the
gene. c) Gene contribution to the pathways in the hub role. Y axis indicates total expression change that the gene induces to its direct downstream
genes. Contribution of the hub role can be either negative or positive. Negative values indicate the gene inhibits its downstream genes while positive
values indicate the gene activates its downstream genes. d) Gene contribution to the pathways. Y axis indicates combined gene contribution of the
bottleneck and hub roles.
pathways (Aurora B signaling, growth hormone signaling,
PLK1 signaling events and LPA4-mediated signaling events)
were validated in at least three independent cohorts (log-
rank p < 0.05; Supplementary File S1).
Our results show poor survival of patients with high
activity of Aurora B signaling or growth hormone signaling
pathway. The roles of growth hormone and Aurora B path-
ways in breast cancer pathogenesis are firmly supported
[18], [19], [20].
Interestingly, PLK1 signaling events pathway showed
the most significant survival association and this association
was supported in all four independent validation cohorts
(Fig.3a-e). Patients with low activity of PLK1 signaling
events pathway have statistically significant survival benefit
as compared to patients with high activity of PLK1 signaling
events pathway. The PLK1 gene plays a critical role in
this pathway; out of all 3,450 signaling flows in the PLK1
signaling events pathway, 979 (28.4%) go through PLK1
(Supplementary File S2). PLK1 directly regulates a number
of cancer progression driver genes, such as CDC20/25C
[21], AURKA [22], ECT2 [23], TPT1 [24] and BUB1 [25]
(Fig. 3f). An example of quantifying gene contribution to
PLK1 signaling events pathway in a single sample is shown
in Supplementary File S2.
Our analysis shows a strongly similar expression pattern
for PLK1 downstream genes (Fig. 3f). Furthermore, PLK1
expression was highly correlated with these direct down-
stream genes (Fig. 3g). This shows how PerPAS can be
used to illustrate pathway activity, which may vary between
samples, to identify genes whose expression patterns are
tightly co-regulated. For example, many expression values
for the majority of genes in the PLK1 signaling events
pathway, e.g., BUB1, CDK1 and CCNB1, correlate strongly
with PLK1. However, there are some genes, such as WEE1,
TPT1 and KIF2A, whose expression values do not correlate
with PLK1. For instance, all upstream regulators for WEE1
(PLK1, CCNB1 and CDK1; Fig.3f) correlate with each other
whereas WEE1 itself does not. Regulation of PLK1 is affected
by various mechanisms, such as by phosphorylation of
target genes, PLK1 enzyme activity and protein structural
variation. Moreover, PLK1 is an essential regulator in many
functions which have distinctive regulatory features. For
example, in mitotic entry WEE1 is inactivated by PLK1 and
further masked by CDC25B, whereas in G2 DNA damage
PLK1 is degraded resulting in WEE1 activation [26], [27].
PLK1 and WEE1 inhibitors have shown promising preclini-
cal and clinical effects in targeted and combinatorial thera-
pies in cancers [26], [27]. While further interpretation of any
regulatory relationships and mechanisms from any pathway
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Fig. 3. Characteristics of PLK1 signaling events pathway. a-e) Survival association of breast cancer patients to PLK1 signaling events pathway.
PLK1 signaling events pathway was scored by PerPAS and patients were divided into two groups by median value of personalized pathway activity
scores of PLK1 signaling events pathway. Patients with low- and high-activity of this pathway are represented as 1 (blue) and 2 (red), respectively.
Vertical ticks represent censoring events. The X and Y axes represent follow-up time in years and the percentage of survival, respectively. Survival
associated p-value was calculated using log-rank test. f) PLK1 signaling events pathway. Each color bar represents a cancer sample and the cancer
samples are displayed in the same order for each gene. Color of bar denotes the relative expression of genes in each cancer sample compared to
control samples in the TCGA cohort and size of nodes represents the topological importance of the genes. g) Pearson correlation between PLK1
and genes in the pathway in the five cohorts. Note: genes BUB1B, SGOL1, PPP1CB, PPP2CA and SPC24 are excluded in the heatmap since they
are not included in the GEO cohorts.
iments, that are out of scope of this study, PerPAS analysis
can be used to recognize common regulatory features which
are not, at least directly, detectable from RNA expression
data.
2.4 Comparison of PerPAS to iPAS and Pathifier using
breast cancer data
One way to evaluate the performance of a pathway anal-
ysis method is to test whether the identified pathways are
associated with patient survival, for example in analyses of
prognostic subgroups or drug responses. Significant associ-
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TABLE 1
Comparison of survival association between PerPAS, iPAS and Pathifier.
Pathways TCGA GSE1456 GSE3494 GSE4922 GSE7390PerPAS iPAS Pathifier PerPAS iPAS PerPAS iPAS PerPAS iPAS PerPAS iPAS
Growth hormone signaling pathway 0.007 0.001 - 0.00002 0.005 0.005 - 0.004 - - -
PLK1 signaling events 0.004 - - 0.0000007 - 0.009 - 0.006 - 0.0009 -
Aurora B signaling 0.007 - - 0.00005 - 0.001 - 0.007 - 0.004 -
LPA4-mediated signaling events 0.0005 - - 0.05 - 0.02 - 0.006 - - -
Map kinase signaling,pathway 0.001 - - - - - - - - - -
mechanism of protein import into the nucleus 0.004 - - - - - - - - - -
Signaling Pathways in Glioblastoma 0.01 - - - - - - - - - -
Inhibition of cellular proliferation by gleevec - 0.007 0.005 - - - 0.02 - - - -
Keratinocyte differentiation - 0.004 - - - - - - - - -
Mechanism of gene regulation by peroxisome proliferators via ppara - 0.0004 - - - - - - - - -
Validated targets of C-MYC transcriptional repression - 0.005 - - - - - - - - -
Oncostatin M Signaling Pathway - 0.0001 - - - - - - - - -
Senescence and Autophagy - - 0.00005 - - - - - - - -
HIF-1-alpha transcription factor network - - 0.003 - - - - - - - -
Lissencephaly gene (LIS1) in neuronal migration and development - - 0.001 - - - - - - - -
Reelin signaling pathway - - 0.0006 - - - - - - - -
Regulation of nuclear beta catenin signaling and target gene transcription - - 0.008 - - - - - - - -
Note: Patients were divided into two groups by the median value of the pathway scores calculated by each method. The associated p-value
was calculated using log-rank test. ”-” denotes p-value that is larger than 0.05.
ation between patient survival and a pathway strongly sup-
ports the importance of the pathway in cancer progression
or drug resistance. The survival association test, however,
is stringent and the lack of survival association does not
necessarily mean that a pathway is not important in cancer
progression.
To compare the performance of PerPAS to iPAS and
Pathifier, we used identical setting, i.e., the TCGA data
were used as the discovery cohort and the Gene Expression
Omnibus (GEO) data were used as the validation cohorts.
For comparison purpose, we selected similar numbers of
significantly altered pathways using different significance
thresholds for each method, resulting in 40 significantly
altered pathways for PerPAS (q < 1 · 10−60), 40 for iPAS
(q < 1 ·10−60), and 43 pathways for Pathifier (q < 1 ·10−140)
from the discovery cohort. We used t-test to compare path-
way activity scores between cancer and control samples.
iPAS and Pathifier identified six and seven survival
associated pathways in the discovery cohort, respectively
(Table.1). Four pathways (57%) identified by PerPAS were
validate in at least three independent cohorts, whereas from
the pathways identified by iPAS two were validated in one
independent cohort. One pathway identified by iPAS was
also identified by PerPAS (growth hormone signaling path-
way). Growth hormone signaling pathway was validated in
one validation cohort in the iPAS analysis, whereas PerPAS
identified it in three validation cohorts with higher survival
association.
Interestingly, the number of common pathways between
PerPAS, iPAS and Pathifier is very small. The major rea-
son for the differences between PerPAS and the other two
methods is that PerPAS takes topology information into
account. This, however, does not explain small number of
common pathways between iPAS and Pathifier: only one of
the seven pathways identified by Pathifier in the discovery
cohort overlapped with the iPAS results (Table 1). While
comprehensive comparison between iPAS and Pathifier is
out of scope of this study, a reason for discrepancy is that
Pathifier uses all samples together to derive a principal
curve for each pathway and thus does not give estimates
for an individual case-control sample pair like iPAS. Fur-
thermore, pathways identified by Pathifier could not be
validated in the independent cohorts because they lacked
control samples. The requirement of control samples is a key
limitation for Pathifier as not all the cohorts contain control
samples.
3 DISCUSSION
Identification of pathways that are altered in tumors com-
pared to controls and drive cancer progression or drug
resistance is a prerequisite for personalized medicine. There
is a pressing need for pathway analysis methods that work
at a single cancer sample level, and are able to pinpoint
the most important pathways and their central nodes in
an individual samples. However, most of existing pathway
analysis methods compare two or more groups of samples
and do not support pathway analysis at a single sample
level. Further, those pathway analysis methods that support
analysis of a single sample do not integrate pathway topol-
ogy. Herein presented PerPAS allows both single-sample
analysis and takes network topology into account.
We have used both synthetic and breast cancer expres-
sion data to demonstrate the utility of PerPAS. Results from
synthetic data demonstrated that PerPAS is able to prioritize
nodes that are central for the network signaling. In the
breast cancer data, PerPAS identified seven pathways with
survival association in the discovery cohort from which
four were validated in at least three independent validation
cohorts. While pathway’s survival association is a stringent
criterion, it is one of the most useful tests for pathway
methods as the users of pathway methods typically are
interested in finding pathways that may have clinical signif-
icance. PLK1 signaling events pathway was associated with
survival in all five breast cancer cohorts. PerPAS highlighted
the PLK1 gene as a central node in the pathway, it was also
highly correlated with most of its downstream genes.
Standardization of gene expression in PerPAS is an im-
portant step to minimize cohort effects. It provides compa-
rability between expression data and between results from
the data. In an ideal case, a set of control samples from
the same cohort is used to standardize gene expression of
treatment samples. PerPAS can also be used without control
samples, for example, by standardizing gene expression to
the mean of the cohort or by skipping standardization step
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in case only one or a few samples are available. PerPAS is
applicable to conduct pathway analysis for gene expression
data from any disease. We have shown here that PerPAS
is applicable to gene expression data. However, PerPAS
should also be applicable to many other molecular data,
such as protein-protein interaction data. PerPAS requires
molecular measurements and networks as its inputs.
In summary, we have developed a novel pathway anal-
ysis method, PerPAS, that is optimized for single sample
analysis. PerPAS uses pathway topology information to
quantify pathway activity scores, and to identify aberrant
pathways and key nodes in the pathways. Our results show
that survival associated pathways identified by PerPAS have
a much higher rate of being validated in the independent





Data preprocessing consists of two steps: standardization of
gene expression and preparation of pathways.
4.1.1.1 Standardization of gene expression: We
adopted the method used by Maxime et al. [13] to stan-
dardize gene expression. Briefly, for expression cohorts that
contain control samples (e.g., TCGA data), gene expression
of a tumor sample is standardized to the mean and the stan-
dard deviation of control samples. We extended this method
to gene expression cohorts that lack control samples (e.g.,
GEO data sets). Gene expression is normalized by the mean
and the standard deviation of the cohort, instead of using
external control samples. This measures gene expression
difference between a tumor sample and the mean of gene
expression of all the tumor samples in the cohort.
4.1.1.2 Preparation of pathways: We obtained path-
ways from NCI-Nature Pathway Interaction Database (PID)
[28] and WikiPathways [29]. Level 3 biopax-formatted PID
was analyzed using rBiopaxParser package [30]. We ob-
tained WikiPathways from Moksiskaan database where
many useful application programming interfaces (APIs) are
provided to ease extraction of different types of interactions,
such as gene activation and inhibition interactions for each
pathway [31]. We excluded pathways with less than four
nodes resulting in 368 pathways from the PID and 75
pathways from WikiPathways.
4.1.2 Quantification of gene contribution to a pathway
Some nodes in a pathway are more central and important
than others. Examples of such central nodes are hubs [15],
[16] and bottlenecks [17]. Contribution of a gene to a path-
way can be quantified according to its hub and bottleneck
roles. Impact of a hubness of a gene can be evaluated by
measuring the number of genes it directly regulates and
expression changes of its direct downstream genes. Quan-




l∈ {direct downstream genes of gene i in the pathway k} Slj
Mi
(1)
where Slj is standardized expression of gene l in sample
j and Mi is the number of direct downstream genes of
gene i. In cases where there are no more than two direct
downstream genes for a gene, a hub score is represented by
its own standardized expression.
Bottleneck measures essentiality of genes in controlling
signaling flows in the pathway [17]. Bottleneck role of a gene
can be quantified by estimating the percentage of signaling
flows that go through the gene over all the signaling flows.
A signaling flow can be considered as a path from one
gene to another. Identification of all possible paths from
one gene to another in a pathway is computationally costly
and furthermore identifying all the paths between all genes
is infeasible, especially when the pathway is complicated.
Hence, we use a shortest path to represent a signaling flow
between two genes [17], which leads to an assumption that
is signaling from one gene to another always transmits
through the shortest path. The shortest path is a path be-
tween two nodes where the sum of weights of its constituent
edges is minimal. In our method, weights of edges are equal
and thus, can be ignored. A breadth-first search algorithm
is used to find shortest paths between any two genes in
a pathway. Quantification of bottleneck role of a gene is





where Nk is the total number of signaling flows in pathway
k and nik is the number of signaling flows to which gene i
contributes. Value of Qik ranges from zero to one.
Finally, given a case sample j, topological contribution of
gene i to pathway k is represented by multiplication of hub
and bottleneck roles of the gene shown in Eq. 3.
Cijk = Qik ·Hijk (3)
4.1.3 Personalized pathway activity score
Personalized pathway activity is the activity of a pathway in
a particular sample. It is summarized from the topological
contribution of all genes in the pathway. Given a pathway k






To assess the significance of personalized pathway ac-
tivity score, two permutation tests are performed under the
null hypothesis of “personalized pathway activity score is
random”. In the first test, PerPAS is applied over 100 ran-
dom trials where the gene expression of the pathway in the
sample is randomly permuted. The second test randomly
assigns gene regulations (edges) to any two genes in the
pathway followed by PerPAS scoring. This procedure is
repeated 100 times. The significant level of both tests is
calculated by comparing the observed score to the mean of
random scores on permutations. Both ways of randomiza-
tion disrupt expression correlation between genes of a gene
regulation. In the first permutation, the topology of path-
way remains, and hence the test answers how randomizing
expression of genes changes personalized pathway activity
score. The second test permutes pathway topology and
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thus tests how topology influences personalized pathway
activity score.
4.2 Breast cancer data
Log2 transformed level 3 RNA-seq gene expression data
were downloaded from The Cancer Genome Atlas (TCGA)
repository [32] and were used as the discovery cohort. We
discarded samples without survival time or vital status
information, resulting in 984 breast cancer samples and 111
control samples. For validation, we used four publicly avail-
able breast cancer data cohorts from Gene Expression Om-
nibus (GEO) [33]: GSE1456 (n = 159), GSE3494 (n = 251),
GSE4922 (n = 236) and GSE7390 (n = 198). For these GEO
data cohorts, gene level normalization was performed by
using Robust Multi-array Average (RMA) and the data were
log2 transformed.
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Sigrid Jusélius foundation, Finnish Cancer Associations and
Integrative Life Science Graduate Program (ILS).
REFERENCES
[1] S. J. Schnitt, “Classification and prognosis of invasive breast can-
cer: from morphology to molecular taxonomy,” Modern Pathology:
An Official Journal of the United States and Canadian Academy of
Pathology, Inc, vol. 23 Suppl 2, pp. S60–64, May 2010.
[2] T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geysers, H. Johnsen,
T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen,
H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. Lonning,
and A. L. Borresen-Dale, “Gene expression patterns of breast car-
cinomas distinguish tumor subclasses with clinical implications,”
Proceedings of the National Academy of Sciences of the United States of
America, vol. 98, no. 19, pp. 10 869–10 874, Sep. 2001.
[3] B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B.
Chakravarthy, Y. Shyr, and J. A. Pietenpol, “Identification of hu-
man triple-negative breast cancer subtypes and preclinical models
for selection of targeted therapies,” The Journal of Clinical Investiga-
tion, vol. 121, no. 7, pp. 2750–2767, Jul. 2011.
[4] R. T. Lawrence, E. M. Perez, D. Hernandez, C. P. Miller, K. M.
Haas, H. Y. Irie, S.-I. Lee, C. A. Blau, and J. Villen, “The proteomic
landscape of triple-negative breast cancer,” Cell Reports, vol. 11,
no. 4, pp. 630–644, Apr. 2015.
[5] G. Ciriello, R. Sinha, K. A. Hoadley, A. S. Jacobsen, B. Reva, C. M.
Perou, C. Sander, and N. Schultz, “The molecular diversity of
Luminal A breast tumors,” Breast Cancer Research and Treatment,
vol. 141, no. 3, pp. 409–420, Oct. 2013.
[6] C. J. Creighton, “The molecular profile of luminal B breast cancer,”
Biologics: Targets & Therapy, vol. 6, pp. 289–297, 2012.
[7] F. Ades, D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fu-
magalli, E. de Azambuja, G. Viale, C. Sotiriou, and M. Piccart,
“Luminal B breast cancer: molecular characterization, clinical
management, and future perspectives,” Journal of Clinical Oncology:
Official Journal of the American Society of Clinical Oncology, vol. 32,
no. 25, pp. 2794–2803, Sep. 2014.
[8] A. L. Tarca, S. Draghici, P. Khatri, S. S. Hassan, P. Mittal, J.-S. Kim,
C. J. Kim, J. P. Kusanovic, and R. Romero, “A novel signaling
pathway impact analysis,” Bioinformatics (Oxford, England), vol. 25,
no. 1, pp. 75–82, Jan. 2009.
[9] W. A. Haynes, R. Higdon, L. Stanberry, D. Collins, and E. Kolker,
“Differential Expression Analysis for Pathways,” PLoS Comput
Biol, vol. 9, no. 3, p. e1002967, Mar. 2013.
[10] C. Liu, R. Louhimo, M. Laakso, R. Lehtonen, and S. Hautaniemi,
“Identification of sample-specific regulations using integrative
network level analysis,” BMC cancer, vol. 15, p. 319, 2015.
[11] S. Nam, H. R. Chang, K.-T. Kim, M.-C. Kook, D. Hong, C. H.
Kwon, H. R. Jung, H. S. Park, G. Powis, H. Liang, T. Park, and
Y. H. Kim, “PATHOME: an algorithm for accurately detecting
differentially expressed subpathways,” Oncogene, vol. 33, no. 41,
pp. 4941–4951, Oct. 2014.
[12] C. J. Vaske, S. C. Benz, J. Z. Sanborn, D. Earl, C. Szeto, J. Zhu,
D. Haussler, and J. M. Stuart, “Inference of patient-specific path-
way activities from multi-dimensional cancer genomics data using
PARADIGM,” Bioinformatics (Oxford, England), vol. 26, no. 12, pp.
i237–245, Jun. 2010.
[13] T. Ahn, E. Lee, N. Huh, and T. Park, “Personalized identification
of altered pathways in cancer using accumulated normal tissue
data,” Bioinformatics (Oxford, England), vol. 30, no. 17, pp. i422–
429, Sep. 2014.
[14] Y. Drier, M. Sheffer, and E. Domany, “Pathway-based personalized
analysis of cancer,” Proceedings of the National Academy of Sciences,
vol. 110, no. 16, pp. 6388–6393, Apr. 2013.
[15] H. Jeong, S. P. Mason, A.-L. Barab??si, and Z. N. Oltvai, “Lethality
and centrality in protein networks,” Nature, vol. 411, no. 6833, pp.
41–42, May 2001.
[16] R. Albert, H. Jeong, and A.-L. Barabasi, “Error and attack tolerance
of complex networks : Article : Nature,” Nature, vol. 406, no. 6794,
pp. 378–382, Jul. 2000.
[17] H. Yu, P. M. Kim, E. Sprecher, V. Trifonov, and M. Gerstein, “The
Importance of Bottlenecks in Protein Networks: Correlation with
Gene Essentiality and Expression Dynamics,” PLOS Comput Biol,
vol. 3, no. 4, p. e59, Apr. 2007.
[18] D. S. Boss, J. H. Beijnen, and J. H. M. Schellens, “Clinical expe-
rience with aurora kinase inhibitors: a review,” The Oncologist,
vol. 14, no. 8, pp. 780–793, Aug. 2009.
[19] J. F. Hilton and G. I. Shapiro, “Aurora kinase inhibition as an
anticancer strategy,” Journal of Clinical Oncology: Official Journal of
the American Society of Clinical Oncology, vol. 32, no. 1, pp. 57–59,
Jan. 2014.
[20] R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn,
C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, and S. A. Narod,
“Triple-Negative Breast Cancer: Clinical Features and Patterns of
Recurrence,” Clinical Cancer Research, vol. 13, no. 15, pp. 4429–4434,
Aug. 2007.
[21] R. Bagheri-Yarmand, A. Nanos-Webb, A. Biernacka, T. Bui, and
K. Keyomarsi, “Cyclin E deregulation impairs mitotic progression
through premature activation of Cdc25c,” Cancer Research, vol. 70,
no. 12, pp. 5085–5095, Jun. 2010.
[22] N. Ertych, A. Stolz, A. Stenzinger, W. Weichert, S. Kaulfu??,
P. Burfeind, A. Aigner, L. Wordeman, and H. Bastians, “Increased
microtubule assembly rates influence chromosomal instability in
colorectal cancer cells,” Nature Cell Biology, vol. 16, no. 8, pp. 779–
791, Aug. 2014.
[23] V. Justilien, L. Jameison, C. J. Der, K. L. Rossman, and A. P. Fields,
“Oncogenic activity of Ect2 is regulated through protein kinase C
iota-mediated phosphorylation,” The Journal of Biological Chemistry,
vol. 286, no. 10, pp. 8149–8157, Mar. 2011.
[24] R. Amson, S. Pece, J.-C. Marine, P. P. Di Fiore, and A. Tel-
erman, “TPT1/ TCTP-regulated pathways in phenotypic repro-
gramming,” Trends in Cell Biology, vol. 23, no. 1, pp. 37–46, Jan.
2013.
[25] Y. Ding, C. G. Hubert, J. Herman, P. Corrin, C. M. Toledo, K. Skutt-
Kakaria, J. Vazquez, R. Basom, B. Zhang, J. K. Risler, S. M. Pollard,
D.-H. Nam, J. J. Delrow, J. Zhu, J. Lee, J. DeLuca, J. M. Olson, and
P. J. Paddison, “Cancer-Specific requirement for BUB1b/BUBR1 in
human brain tumor isolates and genetically transformed cells,”
Cancer Discovery, vol. 3, no. 2, pp. 198–211, Feb. 2013.
[26] B. T. Gjertsen and P. Sch??ffski, “Discovery and development of the
Polo-like kinase inhibitor volasertib in cancer therapy,” Leukemia,
vol. 29, no. 1, pp. 11–19, Jan. 2015, 00040.
[27] P. C. D. W. Hamer, S. E. Mir, D. Noske, C. J. F. V. Noorden, and
T. W??rdinger, “WEE1 Kinase Targeting Combined with DNA-
Damaging Cancer Therapy Catalyzes Mitotic Catastrophe,” Amer-
ican Association for Cancer Research, vol. 17, no. 13, pp. 4200–4207,
Jul. 2011, 00088.
8
[28] C. F. Schaefer, K. Anthony, S. Krupa, J. Buchoff, M. Day, T. Hannay,
and K. H. Buetow, “PID: the Pathway Interaction Database,”
Nucleic Acids Research, vol. 37, no. Database issue, pp. D674–679,
Jan. 2009.
[29] T. Kelder, M. P. van Iersel, K. Hanspers, M. Kutmon, B. R. Conklin,
C. T. Evelo, and A. R. Pico, “WikiPathways: building research com-
munities on biological pathways,” Nucleic Acids Research, vol. 40,
no. Database issue, pp. D1301–D1307, Jan. 2012.
[30] F. Kramer, M. Bayerlov??, F. Klemm, A. Bleckmann, and T. Beiss-
barth, “rBiopaxParser–an R package to parse, modify and visual-
ize BioPAX data,” Bioinformatics (Oxford, England), vol. 29, no. 4,
pp. 520–522, Feb. 2013.
[31] M. Laakso and S. Hautaniemi, “Integrative platform to translate
gene sets to networks,” Bioinformatics (Oxford, England), vol. 26,
no. 14, pp. 1802–1803, Jul. 2010.
[32] Cancer Genome Atlas Network, “Comprehensive molecular por-
traits of human breast tumours,” Nature, vol. 490, no. 7418, pp.
61–70, Oct. 2012.
[33] R. Edgar, M. Domrachev, and A. E. Lash, “Gene Expression
Omnibus: NCBI gene expression and hybridization array data
repository,” Nucleic Acids Research, vol. 30, no. 1, pp. 207–210, Jan.
2002.
